Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa Study of NOX H94 in Anemia of Chronic Disease in Multiple Myeloma or Lymphoma
DRKS00004366Phase 2Recruiting
- Sponsor
- TME Pharma
- Start
- Sep 2012
- Modality
- RNA Aptamers → RNA Therapeutics → Nucleic Acid Therapeutics, DNA Aptamers → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 3
01
Overview
A Phase 2 trial of lexaptepid pegol in anemia of inflammation (AI), multiple myeloma (MM), lymphoma, cancer-associated anemia (CRA), sponsored by TME Pharma. Started Sep 2012; status: recruiting.
02
Drugs
lexaptepid pegol
03
Conditions
anemia of inflammation (AI)multiple myeloma (MM)lymphomacancer-associated anemia (CRA)
Beyond the preview
Go deeper on DRKS00004366.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00004366.